acne inversa - M12-555 -Extention
Laufzeit: 01.01.2012 - 31.12.2014
Kurzfassung
A Phase 3 Open-Label Study of the Safety and
Efficacy of Adalimumab in Subjects with Moderate
to Severe Hidradenitis Suppurativa
Laufzeit: 01.01.2012 - 31.12.2014
A Phase 3 Open-Label Study of the Safety and
Efficacy of Adalimumab in Subjects with Moderate
to Severe Hidradenitis Suppurativa
